Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.
Proposed new cut-off levels for values of very long-chain fatty acids, or VLCFAs — whose buildup characterizes X-linked adrenoleukodystrophy (X-ALD) — ... Read more
Elevated blood levels of a nerve cell-derived component known as neurofilament light chain (NfL) could be a potential biomarker for myelopathy — ... Read more
Data from the Starbeam Phase 2/3 trial continues to support the safety and effectiveness of the gene therapy candidate elivaldogene autotemcel (eli-cel, ... Read more
Treatment with certain epigenetic medicines may help compensate for a deficiency in the ABCD1 gene in patients with adrenoleukodystrophy (ALD), a ... Read more
A new genetically modified earthworm model, Caenorhabditis elegans (C. elegans), mimics the features of human X-linked adrenoleukodystrophy (X-ALD), and could help in more quickly finding ... Read more
Measuring the levels of three biomarkers in the blood may help identify newborns at risk of X-linked adrenoleukodystrophy (X-ALD), a Chinese ... Read more
Immune cells derived from blood samples of people with adrenoleukodystrophy (X-ALD) may help in evaluating their inflammatory status of patients and likely ... Read more
Viking Therapeutics plans to launch a first clinical trial for VK0214, its investigational oral small molecule to treat adrenoleukodystrophy in 2020, the company announced. Adrenoleukodystrophy (ALD), ... Read more
Newborn screening for adrenoleukodystrophy (ALD), including the monitoring and treatment of poor function of the adrenal glands, can prevent the development ... Read more
